Patients with HR-positive, HER2-negative metastatic breast cancer should be consistently tested for ESR1 mutations to inform next lines of therapy.

Bpgbio Inc. has synthesized bifunctional compounds comprising an E2 ubiquitin ligase binding ligand covalently linked to an estrogen receptor α (ER-α; ESR1) targeting moiety through a linker acting as ...

Women with advanced breast cancer who progress on prior CDK4/6 inhibition can still benefit from second-line treatment with a ...

Primary end points were investigator-assessed progression-free survival with imlunestrant as compared with standard therapy among patients with ESR1 mutations and among all patients and with ...

Panelists discuss how molecular testing and liquid biopsies are crucial for tracking estrogen receptor 1 (ESR1) mutations in ...

Elacestrant significantly improves PFS in ER-positive, HER2-negative metastatic breast cancer with ESR1 mutations compared to standard-of-care treatments. The EMERALD trial showed elacestrant's ...

Imlunestrant improved PFS in ESR1-mutated breast cancer compared to standard endocrine therapy, but not significantly in the overall population. Combining imlunestrant with Verzenio enhanced PFS in ...

Panelists discuss how to approach second-line therapy decisions for patients with metastatic breast cancer, emphasizing the importance of biomarker testing, including ESR1 mutations, and considering ...

The novel trial design used ctDNA monitoring at the time of routine tumor scan visits to identify patients for early signs of endocrine resistance and the emergence of ESR1 mutations. Following ...

Some people with ER-positive, HER2-negative breast cancer develop changes in a gene called ESR1 after taking these medicines, which can make them less effective. As a result, the cancer may get worse.

Researchers have identified a subset of brain cells in mice that act as the master regulators of urination. Researchers have identified a subset of brain cells in mice that act as the master ...